On August 1, biopharmaceutical company Sanofi announced the signing of an asset purchase agreement with Viazhen, a subsidiary of biotech company Arrowhead. Viazhen is currently developing and commercializing Arrowhead's four cardiovascular metabolic drug candidates in Greater China. Under the agreement, Sanofi will obtain the right to develop and commercialize the drug under development, preslan sodium injection in Greater China.

Zhitongcaijing · 08/01/2025 11:17
On August 1, biopharmaceutical company Sanofi announced the signing of an asset purchase agreement with Viazhen, a subsidiary of biotech company Arrowhead. Viazhen is currently developing and commercializing Arrowhead's four cardiovascular metabolic drug candidates in Greater China. Under the agreement, Sanofi will obtain the right to develop and commercialize the drug under development, preslan sodium injection in Greater China.